AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37830944 — intervention group
Group type: COMPARATOR
Intervention: Radical resection (RR)
Number of subjects: 183
Study 37830944 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 183
Study 37831046 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate3 LVAD
Number of subjects: 2200
Study 37831045 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Number of subjects: 8232
Study 37831045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8232
Study 37831074 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous anti-IL-6R therapy
Number of subjects: 3
Study 37831125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake reminder
Number of subjects: 84
Study 37831212 — intervention group
Group type: EXPERIMENTAL
Intervention: DEEP-guided ablation
Number of subjects: 40
Study 37831212 — intervention group
Group type: COMPARATOR
Intervention: non-DEEP (fixed-substrate-guided) ablation
Number of subjects: 40
Study 37831378 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimpod electromyograph
Number of subjects: 23
Study 37831433 — intervention group
Group type: EXPERIMENTAL
Intervention: New prognostic model based on four variables: past deterioration, neutrophil proportion > 70%, Na < 128 mmol/L, and vasopressor use.
Number of subjects: 316
Study 37831433 — intervention group
Group type: COMPARATOR
Intervention: Conventional prognostic models.
Number of subjects: 316
Study 37831433 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (no specific intervention mentioned).
Number of subjects: 316
Study 37831448 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-VTE prognostic model with pediatric hematologist review
Number of subjects: 17427
Study 37831448 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis recommendations
Number of subjects: 17427
Study 37831448 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 17427
Study 37831448 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17427
Study 37831485 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention focusing on PrEP use and concomitant stimulant use or CAS
Number of subjects: 70
Study 37831485 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention with financial incentives for documented evidence of PrEP clinical evaluation and filling a PrEP prescription
Number of subjects: 70
Study 37831485 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-stage intervention (MI+CM or CM+MI)
Number of subjects: 70
Study 37831485 — intervention group
Group type: COMPARATOR
Intervention: Assessments only (control group)
Number of subjects: 70
Study 37831490 — intervention group
Group type: EXPERIMENTAL
Intervention: Woebot (8-week digital mental health intervention)
Number of subjects: 202
Study 37831494 — intervention group
Group type: EXPERIMENTAL
Intervention: Transauricular vagus nerve stimulation
Number of subjects: 18
Study 37831494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 18
Study 37831492 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program (HMP)
Number of subjects: 80
Study 37831492 — intervention group
Group type: COMPARATOR
Intervention: Wellness App (WA)
Number of subjects: 80
Study 37831493 — intervention group
Group type: EXPERIMENTAL
Intervention: Managing Stress
Number of subjects: 163
Study 37831493 — intervention group
Group type: EXPERIMENTAL
Intervention: Basics
Number of subjects: 163
Study 37831493 — intervention group
Group type: COMPARATOR
Intervention: Breathing exercises
Number of subjects: 163
Study 37831493 — intervention group
Group type: COMPARATOR
Intervention: Audiobook (active control)
Number of subjects: 163
Study 37831493 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 163
Study 37831682 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration-Controlled Transient Elastography (VCTE)
Number of subjects: 2866
Study 37831682 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Attenuation Parameter (CAP)
Number of subjects: 2866
Study 37831737 — intervention group
Group type: EXPERIMENTAL
Intervention: TauroPace
Number of subjects: 631
Study 37831737 — intervention group
Group type: COMPARATOR
Intervention: H2O2
Number of subjects: 631
Study 37831815 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count decrease by ≥ 25% from day 1 to day 3
Number of subjects: 249
Study 37831815 — intervention group
Group type: COMPARATOR
Intervention: Baseline platelet count
Number of subjects: 249
Study 37831917 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor Dance
Number of subjects: 0
Study 37831917 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 0
Study 37831941 — intervention group
Group type: EXPERIMENTAL
Intervention: HRF (OCT+/CFP-) extent
Number of subjects: 140
Study 37831941 — intervention group
Group type: EXPERIMENTAL
Intervention: HPA extent
Number of subjects: 140
Study 37832036 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic analysis of Cryptosporidium parvum isolates from Bangladeshi infants
Number of subjects: 0
Study 37832036 — intervention group
Group type: COMPARATOR
Intervention: Genomic analysis of Cryptosporidium parvum isolates from the United Kingdom
Number of subjects: 0
Study 37832036 — intervention group
Group type: EXPERIMENTAL
Intervention: Human isolates from both locations
Number of subjects: 0
Study 37832036 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic diversity of C. parvum
Number of subjects: 0
Study 37832128 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral Position (NP)
Number of subjects: 8
Study 37832128 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Rotated
Number of subjects: 8
Study 37832128 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Rotated with Arm Hyperabducted
Number of subjects: 8
Study 37832128 — intervention group
Group type: COMPARATOR
Intervention: Head Rotated (ipsilateral or contralateral)
Number of subjects: 8
Study 37832323 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided in-session exposure with minimally-guided exposure at home (TGE)
Number of subjects: 55
Study 37832323 — intervention group
Group type: COMPARATOR
Intervention: Parent-guided out-session homework (PGE)
Number of subjects: 55
Study 37832323 — intervention group
Group type: COMPARATOR
Intervention: Minimally-guided exposure (MGE)
Number of subjects: 55
Study 37832571 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental regimens composed of different combinations of rifampicin (R), isoniazid (H), pyrazinamide (Z), ethambutol (E), moxifloxacin (M), and SQ109 (Q).
Number of subjects: 397
Study 37832571 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatment regimen.
Number of subjects: 397
Study 37832606 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable (BE) valve
Number of subjects: 396
Study 37832606 — intervention group
Group type: COMPARATOR
Intervention: Self-expanding (SE) valve
Number of subjects: 396
Study 37832758 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg once daily for 6 months
Number of subjects: 100
Study 37832758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 37832982 — intervention group
Group type: EXPERIMENTAL
Intervention: GPi-DBS
Number of subjects: 98
Study 37832982 — intervention group
Group type: COMPARATOR
Intervention: STN-DBS
Number of subjects: 98
Study 37832989 — intervention group
Group type: EXPERIMENTAL
Intervention: ECO threshold of 6 ppm
Number of subjects: 766
Study 37832989 — intervention group
Group type: EXPERIMENTAL
Intervention: ECO threshold of 7 ppm
Number of subjects: 766
Study 37832989 — intervention group
Group type: EXPERIMENTAL
Intervention: ECO threshold of 8 ppm
Number of subjects: 766
Study 37832989 — intervention group
Group type: EXPERIMENTAL
Intervention: ECO threshold of 9 ppm
Number of subjects: 766
Study 37833046 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency spinal cord stimulation (SCS)
Number of subjects: 9
Study 37833194 — intervention group
Group type: EXPERIMENTAL
Intervention: High PEEP (12 cmH2O) with recruitment manoeuvres (RM)
Number of subjects: 48
Study 37833194 — intervention group
Group type: COMPARATOR
Intervention: Low PEEP (3.7 cmH2O)
Number of subjects: 48
Study 37833387 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD) patients
Number of subjects: 93
Study 37833387 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD)
Number of subjects: 93
Study 37833387 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 93
Study 37833472 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 2 mg given six hours after interscalene block
Number of subjects: 73
Study 37833472 — intervention group
Group type: COMPARATOR
Intervention: Placebo given six hours after interscalene block
Number of subjects: 73
Study 37833472 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 2 mg
Number of subjects: 73
Study 37833472 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone 2 mg and Placebo
Number of subjects: 73
Study 37833493 — intervention group
Group type: EXPERIMENTAL
Intervention: HSK21542 (2 μg/0.212 μCi/kg)
Number of subjects: 0
Study 37833567 — intervention group
Group type: COMPARATOR
Intervention: Summer (SPA 7.2 ± 2.9, p = 0.0002)
Number of subjects: 671
Study 37833567 — intervention group
Group type: COMPARATOR
Intervention: Spring (SPA 7.5 ± 2.9, p = 0.025)
Number of subjects: 671
Study 37833567 — intervention group
Group type: COMPARATOR
Intervention: Fall (SPA 7.6 ± 3, p = 0.038)
Number of subjects: 671
Study 37833567 — intervention group
Group type: COMPARATOR
Intervention: Summer (Energy cost of SPA 2.18 ± 0.83, p = 0.0008)
Number of subjects: 671
Study 37833567 — intervention group
Group type: COMPARATOR
Intervention: Spring (Energy cost of SPA 2.186 ± 0.83, p = 0.017)
Number of subjects: 671
Study 37833567 — intervention group
Group type: COMPARATOR
Intervention: Fall (Energy cost of SPA 2.146 ± 0.75, p = 0.038)
Number of subjects: 671
Study 37833567 — intervention group
Group type: COMPARATOR
Intervention: Summer (Protein oxidation rates 292 ± 117 kcal/day, β = -21.2, p = 0.08)
Number of subjects: 671
Study 37833567 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate and lipid oxidation rates (kcal/day)
Number of subjects: 671
Study 37833567 — intervention group
Group type: COMPARATOR
Intervention: RER and 24-h EE
Number of subjects: 671
Study 37833640 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID-19 patients
Number of subjects: 0
Study 37833640 — intervention group
Group type: COMPARATOR
Intervention: Control group (hospitalized patients with respiratory infections other than COVID-19)
Number of subjects: 0
Study 37833645 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance telerehabilitation (experimental group, n=40)
Number of subjects: 80
Study 37833645 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised exercises (control group, n=40)
Number of subjects: 80
Study 37833651 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) treatment
Number of subjects: 20
Study 37833651 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 20
Study 37833679 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberalized potassium diet (3500 mg dietary K daily)
Number of subjects: 30
Study 37833679 — intervention group
Group type: COMPARATOR
Intervention: Standard potassium restricted diet (<2000 mg dietary K daily)
Number of subjects: 30
Study 37833681 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic RTT
Number of subjects: 925
Study 37833681 — intervention group
Group type: COMPARATOR
Intervention: Comparison across disorders
Number of subjects: 925
Study 37833732 — intervention group
Group type: EXPERIMENTAL
Intervention: AVATAR therapy
Number of subjects: 12
Study 37833737 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making assessed using the CollaboRATE survey
Number of subjects: 305
Study 37833799 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL-C, low apolipoprotein A-1, high triglyceride (TG), high apolipoprotein B (ApoB)
Number of subjects: 457
Study 37833799 — intervention group
Group type: EXPERIMENTAL
Intervention: High LDL-C
Number of subjects: 457
Study 37833799 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count
Number of subjects: 457
Study 37833799 — intervention group
Group type: EXPERIMENTAL
Intervention: PDW
Number of subjects: 457
Study 37833799 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateletcrit
Number of subjects: 457
Study 37833799 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding scores
Number of subjects: 457
Study 37833799 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C and homocysteine
Number of subjects: 457
Study 37834761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg daily
Number of subjects: 35
Study 37834761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 37834963 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic heart failure (ACC/AHA Stage C) at enrolment
Number of subjects: 300
Study 37834963 — intervention group
Group type: EXPERIMENTAL
Intervention: HF stages A, B, and C
Number of subjects: 300
Study 37834963 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA functional classification
Number of subjects: 300
Study 37834963 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical events including mortality, HF hospitalizations, and HF-related healthcare resource utilization
Number of subjects: 300
Study 37835071 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA)
Number of subjects: 10
Study 37835071 — intervention group
Group type: COMPARATOR
Intervention: Sham apheresis
Number of subjects: 10
Study 37835071 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA) combined with B-cell depletion therapy
Number of subjects: 10
Study 37835090 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Intervention (TLI) adapted from the National Diabetes Prevention Program (DPP) for individuals with chronic SCI
Number of subjects: 0
Study 37835090 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral support for caregivers
Number of subjects: 0
Study 37835090 — intervention group
Group type: COMPARATOR
Intervention: Control condition for caregivers
Number of subjects: 0
Study 37835090 — intervention group
Group type: EXPERIMENTAL
Intervention: Lock-step circuit resistance training, calorie-restricted Mediterranean-style diet, and 16 educational sessions
Number of subjects: 0
Study 37835090 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver program
Number of subjects: 0
Study 37835830 — intervention group
Group type: EXPERIMENTAL
Intervention: Morton's extension
Number of subjects: 25
Study 37837240 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact X-ray brachytherapy (CXB) boost
Number of subjects: 141
Study 37837240 — intervention group
Group type: COMPARATOR
Intervention: External beam radiotherapy (EBRT) boost
Number of subjects: 141
Study 37837240 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) surgery
Number of subjects: 141
Study 37837353 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 201
Study 37837353 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 201
Study 37837376 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy regimen during ATI
Number of subjects: 14
Study 37837376 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial staff interactions
Number of subjects: 14
Study 37837376 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial experiences
Number of subjects: 14
Study 37837376 — intervention group
Group type: EXPERIMENTAL
Intervention: Considerations for future trials
Number of subjects: 14
Study 37837462 — intervention group
Group type: EXPERIMENTAL
Intervention: TICK-B
Number of subjects: 160
Study 37837462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough trick
Number of subjects: 160
Study 37837462 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon inflation
Number of subjects: 160
Study 37837462 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 37837493 — intervention group
Group type: EXPERIMENTAL
Intervention: Avène thermal spring water hydrotherapy
Number of subjects: 26
Study 37837493 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hydrotherapy)
Number of subjects: 26
Study 37837629 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative ctDNA positivity
Number of subjects: 100
Study 37837629 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ACT ctDNA positivity
Number of subjects: 100
Study 37837629 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ACT ctDNA
Number of subjects: 100
Study 37837629 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with ctDNA
Number of subjects: 100
Study 37837651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 2511
Study 37837651 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 2511
Study 37837720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing VAD support
Number of subjects: 393
Study 37837942 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment strategies at t0 (time of active suicidal ideation with intent)
Number of subjects: 137
Study 37837989 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy with medical treatment
Number of subjects: 253
Study 37837989 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone (standard of care)
Number of subjects: 253
Study 37838080 — intervention group
Group type: EXPERIMENTAL
Intervention: Surprise Question (SQ)
Number of subjects: 301
Study 37838094 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 0
Study 37838323 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-bowel capsule endoscopy (SB-CE)
Number of subjects: 174
Study 37838555 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 (Ra-223)
Number of subjects: 169
Study 37838555 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline bone alkaline phosphatase (BAP)
Number of subjects: 169
Study 37838556 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with targeted biopsy (TBx)
Number of subjects: 83
Study 37838556 — intervention group
Group type: COMPARATOR
Intervention: Systematic transrectal ultrasound biopsy (SBx)
Number of subjects: 83
Study 37838604 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (1000 mg i.v. administered 24-72 hours before surgery)
Number of subjects: 200
Study 37838604 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered 24-72 hours before surgery)
Number of subjects: 200
Study 37838604 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Number of subjects: 200
Study 37838604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 37838623 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR7280 (200 mg QD, 300 mg QD, 200 mg BID)
Number of subjects: 30
Study 37838623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 37838653 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 161
Study 37838653 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual (control)
Number of subjects: 161
Study 37838662 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth companion intervention package
Number of subjects: 744
Study 37838662 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 744
Study 37838669 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU follow-up clinic intervention
Number of subjects: 41
Study 37838669 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 41
Study 37838672 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Mindfulness-Based Stress Reduction (MBSR) program as add on to usual care
Number of subjects: 240
Study 37838672 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 240
Study 37838686 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength (HGS) during chemotherapy
Number of subjects: 56
Study 37838686 — intervention group
Group type: EXPERIMENTAL
Intervention: Minnesota Manual Dexterity Test (MMDT) during chemotherapy
Number of subjects: 56
Study 37838686 — intervention group
Group type: EXPERIMENTAL
Intervention: European Organization for Research and Treatment of Cancer Quality of Life Module Cancer Related Fatigue (EORTC-QLQ-FA12) during chemotherapy
Number of subjects: 56
Study 37838686 — intervention group
Group type: EXPERIMENTAL
Intervention: Semmes Weinstein Monofilament Test (SWMT) during chemotherapy
Number of subjects: 56
Study 37838727 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored virtual information and coaching/support program (TICAA) + American Cancer Society (ACS) website
Number of subjects: 199
Study 37838727 — intervention group
Group type: COMPARATOR
Intervention: Control group using only ACS website
Number of subjects: 199
Study 37838727 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored virtual information and coaching/support program (TICAA)
Number of subjects: 199
Study 37838795 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumped parameter model for assessing coronary blood flow (CBF) based on clinical imaging and in-vivo data during invasive coronary functional assessment.
Number of subjects: 0
Study 37838795 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical routine tests for assessing ischemic risk in AAOCA patients.
Number of subjects: 0
Study 37838987 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifarotene 50 μg/g
Number of subjects: 121
Study 37838987 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 121
Study 37839272 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant (Saturday and Sunday)
Number of subjects: 41
Study 37839272 — intervention group
Group type: COMPARATOR
Intervention: Modafinil (Monday to Friday)
Number of subjects: 41
Study 37839272 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant-supported bridging
Number of subjects: 41
Study 37839313 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 234
Study 37839313 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel+sapanisertib
Number of subjects: 234